Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Diffusion Pharmaceuticals is a clinical stage company focused on improving the eff...
Diffusion Pharmaceuticals is a clinical stage c...
Luna (NASDAQ:LUNA) develops and manufactures new-generation products for the healt...
Luna (NASDAQ:LUNA) develops and manufactures ne...
Meridian is a fully integrated life science company that develops, manufactures, m...
Meridian is a fully integrated life science com...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical c...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a...
Since the companyâs inception, Tetraphase has developed a robust antibiotics pla...
Since the companyâs inception, Tetraphase has...
Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to address...
Foamix Pharmaceuticals is a specialty pharmaceu...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
Join the National Investor Network and get the latest information with your interests in mind.